A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD

(2020) Meenakshi Bewtra et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease

(2019) Davide Di Fusco et al.   Frontiers in Pharmacology

ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment

(2019) Michel Adamina et al.   Journal of Crohns & Colitis

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

(2019) Joana Torres et al.   Journal of Crohns & Colitis

Interrogating host immunity to predict treatment response in inflammatory bowel disease

(2019) Jonathan L. Digby-Bell et al.   Nature Reviews Gastroenterology & Hepatology

Mongersen (GED-0301) for Active Crohnʼs Disease

(2019) Bruce E. Sands et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease

(2018) Brian G. Feagan et al.   GASTROENTEROLOGY

Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice

(2018) Roberta Izzo et al.   INFLAMMATORY BOWEL DISEASES

Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer

(2018) Edoardo Troncone et al.   Frontiers in Immunology

Unlocking P(V): Reagents for chiral phosphorothioate synthesis

(2018) Kyle W. Knouse et al.   SCIENCE

Reciprocal Regulation Between Smad7 and Sirt1 in the Gut

(2018) Silvia Sedda et al.   Frontiers in Immunology

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides

(2017) Naoki Iwamoto et al.   NATURE BIOTECHNOLOGY

Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death

(2017) Veronica De Simone et al.   Cell Death & Disease

Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

(2016) G. Monteleone et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

(2015) Giovanni Monteleone et al.   NEW ENGLAND JOURNAL OF MEDICINE

A functional role for Smad7 in sustaining colon cancer cell growth and survival

(2014) C Stolfi et al.   Cell Death & Disease

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease

(2012) Giovanni Monteleone et al.   MOLECULAR THERAPY

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell recruitment to the intestinal mucosa

(2008) William W. Agace   TRENDS IN IMMUNOLOGY